NASDAQ:MYLMylan Stock Price, Forecast & News

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYL stock has increased by 9.7% and is now trading at $15.88. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

Mylan is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mylan.

Mylan NV (NASDAQ:MYL) posted its quarterly earnings results on Monday, May, 11th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. The firm had revenue of $2.62 billion for the quarter, compared to analysts' expectations of $2.65 billion. Mylan had a return on equity of 20.00% and a net margin of 0.54%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the company earned $0.82 earnings per share. View Mylan's earnings history.

Mylan updated its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.

12 brokerages have issued twelve-month price targets for Mylan's stock. Their forecasts range from $17.00 to $34.50. On average, they anticipate Mylan's stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 49.6% from the stock's current price. View analysts' price targets for Mylan.

Headlines about MYL stock have been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Mylan.

Mylan saw a increase in short interest in June. As of June 15th, there was short interest totaling 31,480,000 shares, an increase of 13.8% from the May 31st total of 27,660,000 shares. Based on an average daily volume of 7,360,000 shares, the short-interest ratio is currently 4.3 days. Approximately 6.1% of the company's stock are short sold. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%) and Corrado Advisors LLC (0.01%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View institutional ownership trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Corrado Advisors LLC. View insider buying and selling activity for Mylan.

MYL stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. View insider buying and selling activity for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $15.88.

Mylan has a market capitalization of $8.21 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

The official website for Mylan is www.mylan.com.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]